Thong Le

Biotechnology investor Accelerator Corp. lands $51 million, expands in New York City

Accelerator Corp, the Seattle biotechnology investment fund started in Seattle 11 years ago, has raised $51.1 million in capital as part of a first closing of its fourth fund. Accelerator also announced plans to expand operations in New York City with new offices at the Alexandria Center for Life Science in Manhattan’s East Side Medical Corridor…. Read More


Cancer research startup Immune Design files for $60 million IPO

Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed to raise $60 million through an initial public offering. The company Like most biotech companies, Immune Design is losing money. It posted a net loss of $16 million last year, and has compiled an accumulated… Read More


More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation from the family of CEO Jeff Bezos, Seattle-based Adaptive Biotechnologies announced a big $105 million investment. Adaptive, which had previously only raised $15 million, was… Read More


Seattle BioMed lands $9.8M grant to study HIV vaccine

Seattle BioMed has received a $9.8 million grant from National Institute of Allergy and Infectious Diseases to fund the initial phases of a vaccine that could neutralize antibodies against HIV-1. The Seattle non-profit will lead a consortium on the effort that also includes the Rockefeller University, the University of Washington, Seattle Children’s Hospital and the Fred Hutchinson… Read More


With $120M in its pocket, Juno Therapeutics aims to wipe out cancer by rewiring the immune system

One big problem with existing cancer therapies available today like chemotherapy and radiation is the collateral damage. While some medicine can completely kill cancer, it also may destroy healthy, normal cells in one’s body. But Juno Therapeutics, a new Seattle startup that just raised a massive $120 million series A round, thinks it has a… Read More


Cancer research startup Juno Therapeutics raises $120M in massive series A financing

In one of the largest series A venture capital deals this year in the biotechnology sector, Seattle-based Juno Therapeutics has landed $120 million in startup financing in a deal led by Arch Venture Partners and the Alaska Permanent Fund. The cancer research company is a spin out of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer… Read More


Money-losing Dendreon to cut 150 employees in bid to become ‘nimble’ biotech company

Once a rising star in Seattle’s biotechnology community, Dendreon Corp. announced Tuesday that it is reducing its staff by 15 percent in an effort to accelerate a path to profitability and operate “as a leaner, more nimble biotechnology company.” The cuts of about 150 people are the latest setback at Dendreon, which eliminated 500 jobs… Read More


Cancer research startup Immune Design pulls in $32.5 million, plans to raise more

Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more in the series C round if certain milestones are met. Investors in the round include The Column Group, Topspin Partners, as well as existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investment. “Immune Design… Read More

Mitchell Gold

Ex-Dendreon CEO starts healthcare investment fund Alpine BioVentures

Former Dendreon CEO Mitch Gold has partnered with biotechnology stock researcher David Miller to create a new Seattle-based investment firm called Alpine BioVentures. The fund, which was started earlier this year, plans to invest in both public and private companies which are developing “significant innovations in healthcare technology which meaningfully improve the lives of patients.”… Read More


Nanostring IPO disappoints as shares fall 20% on first day

It was a tough first day on the stock market for Seattle’s NanoString Technologies, with shares falling 19.4 percent on Wednesday as the stock closed at $8.06. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, earlier this month planned to sell shares in the range of… Read More


NanoString sets IPO range of $13-$15, plans to trade on Nasdaq under ticker NSTG

Seattle’s NanoString Technologies today set the terms for its upcoming initial public offering, with plans to sell shares in the range of $13 to $15 per share. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, initially filed for an IPO last month…. Read More


Theraclone raises $14M to ID rare human antibodies that could be used to fight disease

Seattle biotechnology company Theraclone Sciences has raised an additional $8 million in equity financing and $6 million in debt, bringing total investment in its series B funding to $50 million. Investors in the round included ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo. “Theraclone… Read More

Jim Olson

Blaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’

Seattle biotechnology startup Blaze Bioscience has raised $8.5 million to continue developing technologies that  are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company, with operations in the South Lake Union area of Seattle, now stands at $9.8 million. Blaze said that the money came from individual… Read More


Former oil trader, Yankees part-owner invests in Kineta

Seattle-based biotech upstart Kineta announced a new investment partnership with RLB Holdings, a Connecticut-based investment firm that partially owns the New York Yankees and is managed by a former Glencore international oil trader. Actual numbers weren’t released, but RLB invested in two of Kineta’s clinical stage drug programs: Kineta One LLC and Kineta Two LLC. Between Kineta… Read More

Bill Gates

Bill Gates backs cancer test startup to create a precise genomic tumor blueprint

Microsoft co-founder Bill Gates is tossing his support behind a Cambridge, Massachusetts company by the name of Foundation Medicine which is developing new tests for cancer.  Gates is among the investors pumping $13.5 million into the company, bringing Foundation’s latest round of financing to $56 million. “Advances in understanding the human genome are having a… Read More


Paul Allen’s Institute for Brain Science to move to Seattle’s South Lake Union area

Seattle’s fast-growing South Lake Union neighborhood is getting another boost — this time from the guy who is largely responsible for its transformation. Paul Allen’s Institute for Brain Science announced today that they will relocate their headquarters from Fremont to Seattle’s South Lake Union neighborhood — the neighborhood that Allen’s Vulcan Real Estate has transformed over… Read More


Resolve Therapeutics lands $5.8M to crack the code on Lupus

Resolve Therapeutics, a 2-year-old Seattle biotechnology spin off from the University of Washington, has raised $5.8 million in new financing from  New Science Ventures, WRF Capital and Easton Capital. The company will use the funds to continue to develop therapeutics for the treatment of Lupus, a life-threatening autoimmune disease that affects 1.5 million people in the United… Read More